NCT06192433

Brief Summary

Introduction and Purpose: In recent years, non-pharmacological treatment methods for dementia patients have been gradually explored. Among these, Transcranial Magnetic Stimulation (TMS) has been proposed as a non-invasive treatment option. However, the optimal frequency and stimulation site for repetitive transcranial magnetic stimulation have not been definitively determined. Methods: This study is a randomized controlled trial. We randomly assigned 30 patients with mild cognitive impairment or dementia to the high-frequency transcranial magnetic stimulation group (40 Hz rTMS) or the moderately high-frequency transcranial magnetic stimulation group (10 Hz rTMS). Stimulation was applied to the bilateral dorsolateral prefrontal cortex (DLPFC). Each patient received a course of treatment for 10 consecutive working days. The high-frequency group received pulses at 40 Hz with an intensity of 40% of the maximum intensity for 2 seconds followed by a 58-second rest period, per set. The moderately high-frequency group received pulses at 10 Hz with an intensity of 90% of the maximum intensity for 4 seconds followed by a 56-second rest period, per set. Each day, patients received 30 sets of stimulation (15 times on the left side and 15 times on the right side), totaling 2400 pulses. Cognitive assessments were conducted on patients before and after the treatment course. Quantitative analysis will be performed using the Statistical Package for the Social Sciences statistical software. The Kolmogorov-Smirnov test will be used to check if the data follows a normal distribution. The chi-squared test will compare differences in baseline categorical variables between the groups, while independent t-tests or the Mann-Whitney U Test will compare baseline differences in continuous variables to assess the effectiveness of random assignment. Analysis of variance (ANOVA) and post-hoc comparisons will be used to compare intergroup and intragroup differences. The significance level is set at α = 0.05.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
18

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 26, 2023

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

October 13, 2023

Completed
3 months until next milestone

First Posted

Study publicly available on registry

January 5, 2024

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 19, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 19, 2024

Completed
Last Updated

November 21, 2024

Status Verified

November 1, 2024

Enrollment Period

9 months

First QC Date

October 13, 2023

Last Update Submit

November 19, 2024

Conditions

Keywords

high-frequency transcranial magnetic stimulationcognitive impairmentDementia

Outcome Measures

Primary Outcomes (6)

  • Clinical Dementia Rating (CDR)

    The Clinical Dementia Rating is an assessment tool that primarily focuses on six domains: memory, orientation, judgment and problem-solving ability, community affairs, home and hobbies, and personal care. The questionnaire consists of two parts: the first part is answered by a caregiver and provides basic information about the individual (standard answers), while the second part is answered by the individual to compare against the answers from the first part. Each domain is scored from 0 to 3, with higher scores indicating more severe symptoms.

    pre treatment / ten days later (post treatment)

  • Mini-Mental State Examination (MMSE)

    The MMSE consists of seven major domains: orientation, attention, memory, language, verbal comprehension, ability to perform tasks, and constructional ability. The total score is 30 points, with a cutoff typically set at 24 points; a score of 23 or lower indicates cognitive impairment.

    pre treatment / ten days later (post treatment)

  • Montreal Cognitive Assessment (MoCA):

    The test consists of 30 points and takes 10 minutes for the individual to complete. The basics of this test include short-term memory, executive function, attention, focus, and more.

    pre treatment / ten days later (post treatment)

  • N-Back Test

    The N-Back task is a series of stimuli that requires participants to respond when the current stimulus matches one presented n times before. In this study, a 2-Back test is used, meaning participants are asked to respond when they detect a stimulus that matches the one presented 2 stimuli ago.

    pre treatment / ten days later (post treatment)

  • Stroop Color Word Test (SWCT)

    Also known as the Color-Word Conflict Test, it requires the individual to quickly read the color of the text (e.g., red, blue, green) rather than its meaning.

    pre treatment / ten days later (post treatment)

  • Wisconsin Card Sorting Test (WCST)

    The WCST involves using four stimulus cards and a reference card. Participants are not informed of the pairing rules (color, shape, number form) and must choose a stimulus card to match with a response card. The tester provides feedback as "correct" or "incorrect." When the participant correctly pairs 10 cards in a row using the same rule, the tester changes the pairing rule. This test assesses the individual's executive function.

    pre treatment / ten days later (post treatment)

Study Arms (2)

High-frequency repetitive transcranial magnetic stimulation group (40Hz)

EXPERIMENTAL

High-Frequency Group (40Hz): Participants in this arm receive high-frequency transcranial magnetic stimulation (rTMS) at 40Hz for a specified duration and intensity on the bilateral dorsolateral prefrontal cortex (DLPFC). The stimulation parameters and rest periods are outlined in the study description.

Device: High-frequency repetitive transcranial magnetic stimulation (40Hz)

Moderately high-frequency repetitive transcranial magnetic stimulation group (10Hz)

ACTIVE COMPARATOR

Moderately High-Frequency Group (10Hz): Participants in this arm receive moderately high-frequency transcranial magnetic stimulation (TMS) at 10Hz for a specified duration and intensity on the bilateral dorsolateral prefrontal cortex (DLPFC). The stimulation parameters and rest periods are outlined in the study description.

Device: Moderately high-frequency repetitive transcranial magnetic stimulation (10Hz)

Interventions

Participants in this group receive high-frequency TMS at 40 Hz. The TMS intervention is applied to the bilateral dorsolateral prefrontal cortex (DLPFC). Each patient undergoes this TMS treatment for a course of 10 consecutive working days. The specific parameters for TMS include pulses at 40 Hz with an intensity set at 40% of the maximum intensity. Each pulse lasts for 2 seconds, followed by a 58-second rest period. On each treatment day, patients receive 30 sets of stimulation, with 15 stimulations applied to the left side and 15 to the right side, totaling 2400 pulses.

High-frequency repetitive transcranial magnetic stimulation group (40Hz)

Participants in this group receive moderately high-frequency TMS at 10 Hz. Similar to the high-frequency group, the TMS intervention targets the bilateral dorsolateral prefrontal cortex (DLPFC) and is administered for a course of 10 consecutive working days. The TMS parameters for this group involve pulses at 10 Hz with an intensity set at 90% of the maximum intensity. Each pulse lasts for 4 seconds, followed by a 56-second rest period. As in the high-frequency group, patients in this group also receive 30 sets of stimulation per treatment day, with 15 stimulations applied to the left side and 15 to the right side, totaling 2400 pulses.

Moderately high-frequency repetitive transcranial magnetic stimulation group (10Hz)

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 60 and above.
  • Have received at least 2 years of education.
  • Diagnosed with dementia or Mild Cognitive Impairment (MCI).
  • Clinical Dementia Rating (CDR) score of ≥0.5.

You may not qualify if:

  • Mental illness.
  • Alcohol or substance addiction.
  • History of heart rhythm disorders.
  • History of epilepsy.
  • History of brain injury.
  • Underwent neurosurgery.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Taipei Hospital, Ministry of Health and Welfare

New Taipei City, ROC, 24213, Taiwan

Location

MeSH Terms

Conditions

DementiaCognitive Dysfunction

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeurocognitive DisordersMental DisordersCognition Disorders

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
Participants: Participants are masked or blinded to their group assignment. This blinding is implemented to reduce potential bias in the study, as participants are unaware of the treatment they receive. Assessors: The individuals who perform the cognitive function assessments are also blinded to the group assignment of the participants. They do not know whether a participant belongs to the high-frequency group (40Hz) or the moderately high-frequency group (10Hz). This dual blinding, of both participants and assessors, is important to ensure the integrity and validity of the study's results."
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This study is a Randomized Controlled Trial designed to investigate the effects of different frequencies of transcranial magnetic stimulation (TMS) as non-pharmacological treatment for patients with mild cognitive impairment or dementia. The trial employs a Parallel Study Design, where two groups of participants are treated concurrently with either high-frequency transcranial magnetic stimulation (40 Hz rTMS) or moderately high-frequency transcranial magnetic stimulation (10 Hz rTMS).
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 13, 2023

First Posted

January 5, 2024

Study Start

July 26, 2023

Primary Completion

April 19, 2024

Study Completion

June 19, 2024

Last Updated

November 21, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will not share

Locations